http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106831574-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-06 |
| filingDate | 2017-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106831574-B |
| titleOfInvention | N-(1,2,3,4-Tetrahydroisoquinolinyl)-ferulamide-O-alkylamines and their applications |
| abstract | The invention belongs to the technical field of medicinal chemistry, and discloses an N-(1,2,3,4-tetrahydroisoquinolinyl)-ferulamide-O-alkylamine compound (I) and a pharmaceutically acceptable compound (I) thereof. Accepted salts, methods of preparation and applications, the structures of which are shown in formula I. The compound (I) of the present invention has good butyrylcholinesterase inhibitory activity, antioxidant activity, and Aβ aggregation inhibitory activity, and has obvious neuroprotective function on PC12 cell injury induced by hydrogen peroxide, indicating that the compound is a Multi-target inhibitors. Further in vivo experiments show a good effect on the treatment of Alzheimer's disease, and the toxicity is low, and has a good clinical application prospect. |
| priorityDate | 2017-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 171.